Notifiable diagnoses
Notifiable diagnoses according to ICD10
All C-diagnoses must be reported, with the exception of C44 Basal cell carcinoma and Squamous cell carcinoma.
In addition, these diagnoses must be reported:
D051:Intraductal carcinoma in situ
D06: Carcinoma in situ of cervix (to be reported on CIN form if colposcopy or conisation has been performed)
D090: Carcinoma in situ in bladder
D091: Carcinoma in situ of second and unspecified urinary tract organs
D30: Benign neoplasm of urinary tract organs (excl. D300). The obligation to notify only applies to a morphological diagnosis: Papillary urothelial neoplasm with low malignancy potential
D32: Benign neoplasm in the membranes of the central nervous system
D33: Benign tumor of brain and other parts of the CNS
D352: Benign tumor of pituitary gland
D353: Benign neoplasm of the ductus craniopharyngealis
D354: Benign neoplasm of the corpus pineale
D3910: Tumour with pathological anatomical evidence uncertain malignancy potential in ovary
D3911: Ovarian tumour with clinically uncertain malignancy potential
D3920: Tumour with pathological anatomical evidence uncertain malignant potential in placenta - applies to invasive molar pregnancy
D3921: Tumour with clinically uncertain placental malignancy potential - applies to invasive molar pregnancy
D41: Tumour with uncertain or unknown malignancy potential in urinary ogans (excl. D410) The obligation to notify only applies to a morphological diagnosis: Papillary urothelial neoplasm with low malignancy potential
D42: Tumor with uncertain or unknown target pot. in CNS membranes. All codes within D42 are subject to notification
D43: Tumor with uncertain/unknown target pot. of the brain and CNS. All codes within D43 are subject to notification
D4430: Tumour with pathological anatomical evidence uncertain malignancy potential in pituitary gland
D4431: Tumour with clinically uncertain pituitary malignancy potential
D4440: Tumour with pathological anatomical evidence uncertain malignancy potential in the craniopharyngeal duct
D4441: Tumour with clinically uncertain malignancy potential in Ductus craniopharyngealis
D4450: Tumour with pathological anatomical evidence uncertain malignancy potential in the corpus pineale
D4451: Tumour with clinically uncertain malignancy potential in the corpus pineale
D45: Polycythemia vera
D46: Myelodysplastic syndromes
D471: Chronic myeloproliferative disease
D473: Hemorrhagic essential thrombocythaemia
D474: Myelofibrosis
C44 Basal cell carcinoma and squamous cell carcinoma
C44 is the ICD10 code for both basal cell carcinomas and other skin cancers (with the exception of malignant melanoma, which has ICD10 code C43).
Basal cell carcinomas and squamous cell carcinomas should not be reported in the clinical notification to the Cancer Registry. Other cancer diagnoses within C44 must be reported on the form for solid tumours.
D39.2 Trophoblastic disease
D39.2 is trophoblastic disease, or disease of the placenta.
The benign trophoblastic tumors complete mola and partial mola should not be reported. All malignant cases should be reported. This includes cases of different levels of malignancy such as persistent trophoblastic disease, plancenta-sit-trophoblastic tumour, invasive mola, choriocarcinoma and epithelioid trophoblastic tumour.
Reporting of progression/relapse/metastases
We are often asked whether progression/relapse/metastases should be reported to the Cancer Registry of Norway via clinical notification. The main rules are as follows:
- All metastases occurring before completion of primary treatment should be reported. This applies to all cancers. As a rule, this is taken care of by the reporting that is done in connection with primary assessment, primary treatment and/or control.
- For cancers that are not included in quality registries, it is not necessary to report via clinical notification progression/relapse/metastases that occur after primary treatment has ended.
- For cancers included in quality registries, progression/relapse/metastases must be reported if there are reports covering this. It can either be separate reports of relapse or choices in specific forms (in assessment, in surgery) that concern metastases or local relapse.
